The Translational Breast Cancer Research Consortium was well represented at the 2022 SABCS Meeting. Presentations included:

Translational Breast Cancer Research Consortium Trial 022 (TBCRC 022): Neratinib and Trastuzumab-Emtansine (T-DM1) for HER2+ Breast Cancer Brain Metastases (BCBM); PD7-03

Circulating Tumor DNA Association with Residual Cancer Burden After Neoadjuvant
Therapy in Triple Negative Breast Cancer in TBCRC 030; PD11-06

Intratumor Heterogeneity and Intrinsic Immune Activation are Associated with Response to Chemotherapy in BRCA-related Breast Cancers (TBCRC 031); P5-12-03

Adjuvant Trastuzumab Emtansine (T-DM1) Versus Paclitaxel plus Trastuzumab (TH) for Stage I HER2+ Breast Cancer: 5-Year Results and Correlative Analyses from ATEMPT (TBCRC033); PD18-01

Using Clinical Characteristics and Molecular Markers to Predict the Risk of Subsequent Ipsilateral Breast Events after Excision of DCIS (TBCRC 038); P1-07-02

TBCRC-053: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer; OT3-15-01

TBCRC-055: A Phase II Study of NirAparib, Dostarlimab, and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR); OT2-09-01

Reasons for Reduced Willingness to Participate in Clinical Trials During the COVID-19 Pandemic: The Translational Breast Cancer Research Consortium (TBCRC 057) Survey;  P6-08-07